Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Research Abstract |
Clinical study has shown that breast cancer patients are improved overall survival by Bisphosphonate (ZOL). We investigated whether ZOL is involved in Epithelial-mesenchymal transition (EMT) in bone. We showed bone environment promotes EMT in breast cancer cells. Moreover, ZOL inhibits EMT in bone via stimulation of EMT inducing factor Snail degradation by preventing its de-ubiquitination by USP45, leading to the suppression of secondary metastases from bone.
|